Takara Bio has announced it has entered into a license agreement with non-profit/charity organisation, Fondazione Telethon Italy, under which Takara Bio grants Telethon a commercial licence to use RetroNectin.
Under this agreement, Takara Bio provides Telethon with reliable supplies of RetroNectin.
The technologies licensed to Telethon are based on Takara Bio’s proprietary RetroNectin method, which includes a technology enabling highly efficient gene transduction to cells by retrovirus/lentivirus vector and expansion of T-cells with high efficiency.
With such advantages, RetroNectin method is one of the mostly used standard protocols utilised for “Engineered Gene Therapy”, which includes promising TCR and CAR gene therapies recently raising higher expectations, as well as “Hematopoietic stem cell Gene Therapy”.
Under the agreement signed with Takara Bio, Telethon is allowed to use RetroNectin for production of its cell & gene therapy products, one of which is Strimvelis, a rare disease treatment targeting Adenosine deaminase deficiency.
Takara Bio is promoting supply of RetroNectin to clinical development of Engineered gene and cell Therapy actively pursued worldwide in recent years, and expects higher sales growth in the future.
